Canbridge Pharmaceuticals (HKSE:01228) Total Equity: HK$-377.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01228 Canbridge Pharmaceuticals Inc HKSE:01228
48 GF Score
Price HK$2.28
GF Value HK$0.37
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals Total Equity?

Canbridge Pharmaceuticals HKSE:01228 +5.81% 48 Total Equity is HK$-377.55 Mil as of Dec. 2025. GuruFocus rates HKSE:01228 with a GF Score™ of 48/100 and a GF Value™ of HK$0.37 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Canbridge Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was HK$-377.55 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Canbridge Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals Total Equity Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 849.04 344.57 -43.52 -506.60 -377.55

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.52 -301.69 -506.60 -447.15 -377.55
HKSE:01228
48GF Score
Canbridge Pharmaceuticals Inc HKSE:01228
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Canbridge Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=182.712-560.257
=-377.55

Canbridge Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=182.712-560.257
=-377.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$-377.55 Mil mean?
Canbridge Pharmaceuticals (HKSE:01228) has a Total Equity of HK$-377.55 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Canbridge Pharmaceuticals and its competitors.
Is Canbridge Pharmaceuticals' Total Equity too high?
Canbridge Pharmaceuticals' current Total Equity is HK$-377.55 Mil. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Total Equity compare to VRTX and REGN?
Canbridge Pharmaceuticals' Total Equity of HK$-377.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Canbridge Pharmaceuticals and its competitors. Canbridge Pharmaceuticals's current Total Equity is HK$-377.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.37, compared to a current price of HK$2.28 — trading 514.9% above its estimated fair value. The current Total Equity is HK$-377.55 Mil. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current Total Equity is HK$-377.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of HK$2.28 is trading 514.9% above its estimated GF Value™ of HK$0.37. GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:01228:

  • Total Equity: HK$-377.55 Mil
  • GF Value™: HK$0.37 vs. price of HK$2.28 (514.9% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for HKSE:01228

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.28
Price
HK$0.37
GF Value